Stem Cell Therapy Treatment for DuchenneMuscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for DuchenneMuscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Stair climbing is easy now. 1....

By: neurogenbsi

Here is the original post:
Stem Cell Therapy Treatment for DuchenneMuscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

Stem Cell Therapy Treatment for Head Injury by Dr Alok Sharma, Mumbai, India.
Improvement seen after Stem Cell Therapy Treatment for Head Injury by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1) Sensations all over the body...

By: neurogenbsi

View original post here:
Stem Cell Therapy Treatment for Head Injury by Dr Alok Sharma, Mumbai, India. - Video

STEM CELL THERAPY discussed in ABS-CBN, UMAGANG KAY GANDA, PUNTO por PUNTO
Please like the official Facebook page of Philippine Medical Association https://www.facebook.com/PhilippineMedicalAssociation Anthony Taberna discusses Lega...

By: PhilMedAssociation

The rest is here:
STEM CELL THERAPY discussed in ABS-CBN, UMAGANG KAY GANDA, PUNTO por PUNTO - Video

Foreign doctors behind illegal stem cell therapy
The Philippine Medical Association wants to go after foreign doctors who are reportedly conducting unauthorized stem cell procedures in the country.

By: TheABSCBNNews

Visit link:
Foreign doctors behind illegal stem cell therapy - Video

MANILA - Two congressmen who died after undergoing stem cell therapy abroad were already sick before getting treatment, Health Secretary Enrique Ona said Tuesday.

Speaking to reporters, Ona refused to say if stem cell treatment caused the deaths of congressmen Erico Aumentado and Pedro Romualdo. Both lawmakers died of pneumonia.

"First hindi ko alam yun. Second, ang information that we got: It has nothing to do Ibig sabihin, they were already very sick bago nagpa-so-called stem call, baka sakali," he said in the interview.

On the other hand, the health secretary said clinics or hospitals in the Philippines offering stem cell treatments should be duly licensed by the Department of Health.

Dapat yung mga clinic or mga ospital na gumagawa noon kailangang mayroong license, approved ngayon ng DOH. Kaya iinspekyunin sila," he said.

House Speaker Sonny Belmonte earlier confirmed Aumentado and Romualdo had died after undergoing stem cell treatment in Germany last year. He clarified that it has not been established whether stem cell therapy was the cause of death.

Belmonte said that after having stem cell therapy, the 2 felt rejuvenated and may have exerted themselves during the last election campaign.

Belmonte said Aumentado even started walking around without a cane.

Aumentado's son, Aristotle, earlier said his father had leg thrombosis for which he had to undergo bifemoral bypass and stem cell therapy .

After stem cell therapy, his father started walking without a cane, and sometimes had low-blood sugar. However, he said they forgot to get him stem cell treatment for his father's pneumonia, which he had before the stem cell treatment in Germany last September.

Here is the original post:
DOH: Solons who died after stem cell therapy were sick

MANILA - A government official on Thursday said he is no believer in stem cell therapy after undergoing the procedure but getting zero health benefits.

Speaking to radio dzMM, Dangerous Drugs Board chairman Antonio "Bebot" Villar said he was enticed to try out the procedure after hearing from other people about the near-miraculous effect of stem cell therapy.

He noted that even former President Joseph Estrada has attributed his rejuvenated health to stem cells.

"Kasi nababalitaan ko maganda itong stem cell. Ako ay madalas na [masakit] ang buto ko. Siguro nanghihina yung buto ko na at tsaka medyo mahina ang katawan ko kaya sinubukan ko ito," he said.

Villar said he paid 16,000 euros or more than P900,000 to Villamedica for stem cell therapy to cure aches and pains in his bones and general body weakness.

He said he underwent treatment with his wife at Makati Shangri-la hotel, along with at least a dozen others.

"July 9 may schedule na stem cell sa Shangri-la EDSA. Mga dose or kinse kami. Halos buong floor, yun chairman doctor kasama assistants na taga-Thailand," he said.

The DDB chief said he received several injections on the buttocks and ordered to stay in the hotel for a day so doctors could monitor their blood pressure. He said the stem cells were harvested from lambs.

He said that after the treatment, he tried to see if he got stronger but only felt worse.

"Ang lakas ng loob ko at naniniwala ako. Naglakad ako. Abay, sumakit ang mga paa ko. Parang wala itong epekto," he said.

View post:
After P900K stem cell therapy, PH official feels worse

Stem Cell Therapy Treatment for Right brachial Plexopathy by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Right brachial Plexopathy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. T...

By: neurogenbsi

Read the original:
Stem Cell Therapy Treatment for Right brachial Plexopathy by Dr Alok Sharma, Mumbai, India. - Video

American Health Journal PBS Special Laminine Stem Cell Therapy Full Version
http://www.LaminiNHealth.com/dc/ Doctors are interviewed about Fibroblast Growth Factor, Laminin, Cortisol, Serotonin Do-It-Yourself Stem Cell Therapy - La...

By: David Dolores

Original post:
American Health Journal PBS Special Laminine Stem Cell Therapy Full Version - Video

HIALEAH (CBSMiami) A team of Hialeah veterinarians performed a groundbreaking medical procedure on a dog to help him walk again.

Brando, a 9-year-old German shepherd, received an innovative two-part stem cell therapy at Paradise Animal Clinic in Hialeah on Wednesday. Its the first time this type of therapy has been performed in Florida.

The dog had been paralyzed from the waist down since January and used a doggie wheelchair to get around.

Vets said that he had a skin infection that paralyzed his lungs and then spread to a disc in his back. The infection caused 80 percent of Brandos leg muscles to weaken.

We were totally emotionally destroyed. Kids were crying, wife was upset, I was upset, said owner Manuel Bouza. Obviously the issue was he was so sick whether we put him down because hes paralyzed or whether we deal with it.

Bouza said that they wanted to do whatever they could to help him. One day, he stumbled across a video on YouTube about a dog in Great Britain who had received a stem cell treatment and he became interested.

With no proven options for recovery, they decided to try an experimental stem cell procedure never performed before in Florida.

This is a last ditch effort, said Bouza.

During the procedure, surgeons took fat from Brandos stomach and processed out the stem cells which were then re-injected into his spinal cord. They hope the cells will regenerate tissue and help Brando become more mobile.

The idea is that stem cells are able to go to a given place in the body and repair, said said animal surgeon Jose Gorostiza. Hopefully they will help the cells that are there function again, the new ones.

View post:
Paralyzed Dog Receives Stem Cell Therapy

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/cn2vq9/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2012, and projected to 2022. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 289 of these are profiled in part II of the report along with tabulation of 278 alliances. Of these companies, 160 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 12 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

See the article here:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - Updated 2013-2022 Global Report

Newswise LOS ANGELES May 30, 2013 Newport Beach-based nonprofit Coalition Duchenne has awarded a $150,000 grant to a Cedars-Sinai Heart Institute team investigating whether an experimental cardiac stem cell treatment could be used to treat Duchenne muscular dystrophy patients who have developed heart disease.

Coalition Duchenne is led by Catherine Jayasuriya, a mother whose 20-year-old son, Dusty Brandom, has cardiomyopathy associated with Duchenne muscular dystrophy. She was inspired to underwrite cardiac stem cell research at Cedars-Sinai after reading about a successful clinical trial led by Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute and the Mark S. Siegel Family Professor.

The experimental stem cell therapy, developed by Marbn, is the only treatment shown in clinical trials to regenerate healthy heart muscle. In the clinical trial, patients underwent biopsies during which doctors removed a piece of heart muscle about the size of half a raisin. The heart tissue was then used to grow specialized heart stem cells, which then were injected back into the patients heart. Results published in The Lancet showed that patients experienced an average 50 percent reduction in muscle damaged by heart attack.

I immediately sensed the potential for applying this rapidly evolving treatment to Duchenne, said Jayasuriya. I made it my personal quest to help get this kind of therapy for Duchenne patients.

Jayasuriyas commitment was further cemented when she discovered that Ron Victor, MD, associate director of the Cedars-Sinai Heart Institute, has been working with Duchenne patients as part of his investigation of the cardiac benefits of sildenafil (Viagra) and tadalafil (Cialis).

We know that boys with Duchenne are born with a small scar in the base of their heart, said Victor, the Burns and Allen Chair in Cardiology Research at the Cedars-Sinai Heart Institute. The damage to hearts in boys with Duchenne increases over time. If we can use stem cells to slow or stop heart damage, it could help stall progression of the disease.

The first step in the study is to examine the effect of injecting cardiac stem cells into the hearts of mice with Duchenne. If the data is positive, the experimental treatment could be rapidly approved for use in humans with Duchenne because of cardiac stem cell treatments have been approved for other patient populations, including those with advanced heart disease.

Each year, 20,000 boys are born with Duchenne, Jayasuriya said, who founded Coalition Duchenne in 2010 to raise global awareness for Duchenne muscular dystrophy, fund research and find a cure for Duchenne. Many do not live into their 20s and we lose many to cardiac issues. We need to focus on changing the course of the disease. We hope that working with cardiac stem cells is one way we will eventually change that outcome.

Duchenne muscular dystrophy is a progressive muscle-wasting disease and the most common fatal disease that affects children. Duchenne occurs in one in 3,500 male births, across all races, cultures and countries. Duchenne is caused by a defect in the gene that produces the protein dystrophin, which helps connect the muscle fiber to the cell membranes. Without dystrophin, muscle cells become unstable, are weakened and lose their functionality. Life expectancy of boys and young men with Duchenne ranges from the mid-teens to the mid-20s. Their minds are unaffected.

The Cedars-Sinai Heart Institute is internationally recognized for outstanding heart care built on decades of innovation and leading-edge research. From cardiac imaging and advanced diagnostics to surgical repair of complex heart problems to the training of the heart specialists of tomorrow and research that is deepening medical knowledge and practice, the Cedars-Sinai Heart Institute is known around the world for excellence and innovations.

Read more:
Grant Funds Research Into Cardiac Stem Cells as Treatment for Heart Disease Related to Duchenne Muscular Dystrophy

LaViv stem cell therapy for acne scars
Dermatologist and cosmetic surgeon Dr. Melanie Palm of http://www.artofskinmd.com discusses and demonstrates the use of LaVIV, the first available personalized stem...

By: melaniepalm

See more here:
LaViv stem cell therapy for acne scars - Video

Bonita Springs, Florida (PRWEB) May 07, 2013

The Alliance for the Advancement of Stem Cell Therapy and Research monetarily supports some of the treatments provided by Intercellular Sciences. The Alliance is a non-profit organization dedicated to promoting research and treatment of life altering diseases with adult stem cells.

Howie Linderman, founding board member of The Alliance, says, The Alliance is very proud to be a part of helping people obtain this breakthrough treatment. When I had my stem cell treatment in 2008, the process was much more complex. This new protocol will change the way the world views cardiac problems and we are excited to participate.

To become a supporting member, please visit http://www.thestemcellalliance.org

John C. and Eddie W. have had Dilated Cardiomyopathy for many years and as time has gone on their heart muscle has continued to weaken. The deterioration of their hearts function deteriorated to the point that walking across the room was impossible without shortness of breath. Eddie had become so bad that he was restricted to a wheelchair. Modern science has not been able to stop the progression of this devastating disease. All the medications and defibrillators can do is treat the symptoms. Both men were facing a very grim prognosis. In March they each underwent a treatment using their own stem cells to regenerate the heart muscle. Within several weeks they were both feeling better and able to do much more activity than before. Eddie was out of his wheel chair. John went back to bowling.

John C. (age 62, Dickson, TN), has had Cardiomyopathy since he was a young man. First diagnosed while in college he has had to adjust his life style to adapt to his weak heart function. His doctors recommended a defibrillator a few years ago and he has been dependent on it since. His symptoms became rapidly progressive in the last couple of months. He had to stop many of his activities including cardiac rehab. It had become just too difficult for him. Johns ejection fraction (the percent of pumping of the heart) had dropped to under 10%. His doctors were not optimistic. He and his wife Karen refused to accept such a grim fate and searched for alternative treatment. They soon found an option: adult stem cell therapy. I have much more energy now, said John after his treatment. Im back to walking the perimeter of my 6 acre property and Im back at cardiac rehab. I have even started bowling again which I had stopped. Karen says that the change has been Amazing! An echocardiogram done 3 weeks after his treatment showed an increase in his ejection fraction of 50%. It is expected that his heart function will continue to improve for up to 6 months.

Eddie W. (age 41, Americus, GA) has battled heart disease for the last 14 years. He went through several years with just mild symptoms but, the last year has been devastating. His heart function deteriorated to such a degree that he has been hospitalized twice recently for severe swelling and shortness of breath. The doctors told his wife Leslie to get his affairs in order. While he was in the hospital this last time his family searched for other options. Coming across adult stem cell treatment for heart disease they took a leap of faith and made arrangements for treatment that has to be done outside the United States. Eddie was so weak that he could only get around being pushed in a wheelchair. He also had a pump attached that delivered a medication called Primacor to help his heart. Leslie had to fill the pump once a day with this life sustaining medicine. Eddie was treated in March. The treatment was a success. Within one week the pump was discontinued. Within two weeks he was getting around without the wheelchair. We hosted a church function and Eddie was able to keep up the whole time. Leslie says He could barely get out of his wheelchair before and now to be hosting a party, I cant believe it. Im so grateful. My boys have their father back. Eddies treatment was in part supported by The Alliance for The Advancement of Stem Cell Therapy and Research.

Zannos G. Grekos, MD, MAAC, FACC, chief science officer of Intercellular Sciences and a Florida-based pioneer in the field of adult stem cell therapy explains how, in this groundbreaking treatment, cardiologists insert a catheter into the patients heart similar to a heart cath. In 20 minutes, about 30 separate injections of Regenocytes (activated stem cells) are introduced into the damaged part of the heart. The process of tissue repair begins almost immediately.

The activation provides a key step in the process, Dr. Zannos Grekos explains. The lab extracts the stem cells, concentrates and activates them into over a billion of regenerative adult stem cells while educating them to assist the specific organ that needs regeneration. These cells we call Regenocytes.

Patients remain in the hospital overnight for observation, and are typically discharged the next day. Patients are scheduled for regular subsequent visits after the stem cell treatment to monitor their progress and measure their results.

Read the original post:
The Alliance for the Advancement of Adult Stem Cell Therapy and Research Recently Has Proven Stem Cells To Be ...

WALTHAM, Mass.--(BUSINESS WIRE)--

ViaCord, PerkinElmers family cord blood and tissue preservation business, is collaborating with the Center for International Blood and Marrow Transplant Research (CIBMTR) to collect, maintain and publish research from ViaCords cord blood stem cell transplants. This collaboration will expand knowledge of cord blood-derived stem cell applications throughout the medical and research community. To date, CIBMTRs large network of transplant centers has resulted in the development of a clinical database of more than 30,000 cord blood transplant recipients for clinical decision-making, use in studies, and other research purposes with the goal of making a profound impact on the survival of cord blood transplant patients around the world. CIBMTR will work directly with ViaCord to collect and analyze data to better understand the quality and any outcome metrics of ViaCords released cord blood stem cell units as well as how the units are being used.

Collaborating with CIBMTR, which has established the industry standard for collecting data around hematopoietic cellular therapy and regenerative medicine, allows us to simultaneously gain insights into the effectiveness of the cord blood stem cell units we have released for use as well as outcomes from their clinical application, said Morey Kraus, Chief Scientific Officer, ViaCord. We are then able to incorporate data from our transplanted units into the larger database, which may be accessed for other CIBMTR studies by the medical and scientific community to further their research and understanding of cord blood stem cells.

ViaCord is working with CIBMTR to collect and publish data as well as identify outcomes unique to related or autologous (stem cells from the same patient) transplants. The collaboration will also enable the analysis of umbilical cord units released for potential future use in autologous cell therapy and regenerative medicine clinical trials, including Cerebral Palsy, Type 1 Diabetes and others.

The science of cord blood and cord tissue stem cells is growing at a rapid pace, said J. Douglas Rizzo, M.D., M.S., Associate Scientific Director, CIBMTR. We are excited to collaborate with ViaCord to provide data and analytic expertise that will assist the development of the field through research.

ViaCord's family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood for potential medical use by the child or a related family member. Families are also preserving their babys umbilical cord tissue because research suggests that one day these special cells may have the potential to treat medical conditions that are untreatable today. ViaCord has preserved the umbilical cord blood of more than 300,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today, cord blood stem cells have been used in the treatment of nearly 80 diseases, including cancers, certain blood disorders and immunodeficiencies. Please visit http://www.viacord.com for more information.

Factors Affecting Future Performance This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About the Center for International Blood and Marrow Transplant Research(CIBMTR) A combined research program of the National Marrow Donor Program and the Medical College of Wisconsin, the CIBMTR facilitates critical, cutting-edge research that has led to increased survival and an enriched quality of life for thousands of patients. The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy research worldwide. The prospective and observational research is accomplished through scientific and statistical expertise, a large network of transplant centers and clinical database of more than 350,000 transplant recipients.

About PerkinElmer, Inc. PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at http://www.perkinelmer.com.

Originally posted here:
ViaCord® to Advance Cord Blood Stem Cell Therapy Research through Collaboration with the Center for International ...

ARAD, Israel, April 2, 2013 /PRNewswire/ --

Andain Inc. (ANDN) ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its incubator program, today discussed and provided an update on its breakthrough, innovative stem cell therapy for treating and regenerating severely damaged muscle tissue.

Andain's innovative stem cell therapy technology rehabilitates and heals damaged muscle tissue by initiating regenerative myogenic cells (cardiac muscle), as well as striated muscle cells (skeletal muscle) growth in damaged tissue sites such as the myocardium (cardiac muscle) following an myocardial infarction (heart attack), limb pressure ulcers, and degenerative muscular diseases. The short term application is directed towards the treatment of patients with peripheral vascular disease, while the long term application is focused on the healing and regeneration of cardiac muscle following acute myocardial infarction or chronic heart failure.

Employing a patient's own cells (autologic transplantation), the Company's unique technology and process diverts the patient's own cells into specific targeted myogenic cells, which can then be inserted into the damaged tissue and accelerates the healing process. The administered myogenic or skeletal stem cells work as a network, acting in exactly the same way that the cells of skeletal and heart muscle tissue perform, and actually replenish the existing cells, thus strengthening the intended injured site following the transplantation process. This process can be utilized for different clinical pathologies as mentioned above and can also be utilized for patient using different donor as the source of the stem cells.

Our developed technology and protocols results in a promising safe regenerative therapy, without side effects, tissue rejection or the requirement of suppressive immunological treatment or malignant tumor hazard. Our technology also provides a simple, fast and safe treatment, overcoming technological difficulties associated with using other stem cell therapies sources such as embryonic, placenta, or umbilical cord blood cells that require cryogenic storage.

Andain's President and CEO Sam Elimelech, commented, "The field of stem cell therapeutics is in its early stages of growth as companies and researchers continue to uncover the vast potential and promising uses for them in the treatment and prevention of countless tissue injuries and diseases. We are in an excellent position to capitalize on the emergence of this new market. It is our belief that Orcell's cutting-edge technology and process is unique in regard to the fact that it allows for the safe and efficient directing of the patients own cells as into myogenic cells or striated muscle cells, thus eliminating the hazards associated with rejection and malignant tumors. Via our industrial incubator platform and expert scientific team, we look forward to helping Orcell commence their clinical trials later this year and make considerable progress of their technology and process closer to market."

Andain's incubator platform is currently undergoing with its stem cell technology a build-up of GLP (Good Laboratory Practice) production line as a preparation for the FDA approval stage with clinical trials scheduled for Q1 2014 at one of the foremost Heart centers in Israel under the direction of Professor Mickey Scheinowitz, one of Israel's leading scientists who gained vast experience in the understanding and treating of cardiovascular diseases.

ABOUT ANDAIN INC

Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain (OTC: ANDN) commercializes novel technologies in the biotech, medical and life sciences fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value. For more information, please visit our website at http://www.andaininc.com.

FORWARD LOOKING STATEMENTS

Here is the original post:
Andain Inc. Discusses and Provides Update on its Breakthrough Stem Cell Therapy for the Treatment and Regeneration of ...

Albany, NY (PRWEB) March 29, 2013

GBI Research, the leading business intelligence provider, has released its latest research Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/155690

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals JR-031 (2014) in Japan and FCB Pharmicells Cerecellgram (CCG) (2015) in South Korea.

Related Report: Mobile Health (mHealth) - Enhancing Healthcare and Improving Clinical Outcomes

The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

Latest Report: Global SMB Web Analytics Market 2012-2016

Scope

Healthcare Report: Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

Originally posted here:
Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report Available at MarketResearchReports.biz

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma After Stem Cell Therapy 1) Ankle dorsiflexion movements are possible now. 2) He is able ...

By: neurogenbsi

More here:
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma - Video

Stem Cell Therapy for Pets - Kye Before After
Amazing before and after footage of Kye, an 11 year old lab who received stem cell therapy for his arthritis. For more information about stem cell therapy fo...

By: NewmanVets

Originally posted here:
Stem Cell Therapy for Pets - Kye Before

The Consumer By Linda Bolido Philippine Daily Inquirer

All the publicity about stem-cell therapy (SCT), including endorsements from some of the countrys most powerful people and brightest stars, has made it seem like a miracle cure, even a cure-all.

From the treatment of life-threatening medical problems to reversing the effects of aging, people are now beginning to look to SCTespecially if they can afford itfor salvation.

But, according to a doctor I know, there are actually only two proven applications for the therapy right now. The rest, at this stage, is really still experimental. People have, of course, volunteered for pioneering procedures, hoping for a cure for whatever ails them.

Education still needed

Thats well and good, as long as they are fully informed and give their unequivocal consent to being experimented on. The problem, however, is some people undergo the therapy without fully understanding it. And there are groups that seem to think that because they have Googled the therapy and read everything on the Net about it, they are capable of doing the procedure.

I mentioned in this column previously that even beauty parlors were offering to do SCT. Although it would be only for cosmetic purposes, the procedure is too new and complex to leave in the hands of beauticians.

Finally, the Department of Health has issued rules and regulations to regulate the SCT practice, a move warmly welcomed by the medical community, particularly the Philippine Medical Association and Philippine Society for Stem Cell Medicine, which expressed concern before that the popularity of SCT would lead to abuse and illegal practice if left unregulated.

Health Secretary Enrique Ona, in published reports, said the guidelines aimed to safeguard the welfare of our patients and the general public by making [sure] safe, effective and ethical stem-cell modalities and practices are within emerging international and global standards considering the very complex nature of this therapy.

Among other things, the rules restrict the use of genetically altered stem cells and tissues of human adults and the umbilical cord, fat-derived human stem cells and live animal stem cells.

More:
New rules will regulate stem- cell therapy use

Dr Alok Sharma #39;s Stem Cell Therapy Treatment for Cerebral Palsy
dr alok sharma stem cell therapy treatment for cerebral palsy He is a case of CP with history of fullterm C section delivery and normal milestones till eight months of age when he had an episode of febrile convulsions Post convulsions he had delayed milestones After Stem Cell Therapy 1 Irrelevant speech which was excessively present before has reduced post therapy 2 His level of understanding has increased and response to following commands has improved considerably upto 25% For eg after ...

By: neurogenbsi

Here is the original post:
Dr Alok Sharma's Stem Cell Therapy Treatment for Cerebral Palsy - Video